Nurix Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1 Clinical Trial Cancer Data for BTK Degrader NX-5948.
Nurix Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1 Clinical Trial Cancer Data for BTK Degrader NX-5948.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.